Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field

Peter Valent*, Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria and Ludwig Boltzmann Cluster Oncology, Währinger Gürtel 18-20, Vienna, Austria

Gerald J Gleich, Department of Dermatology, University of Utah, Salt Lake City, UT, USA

Andreas Reiter, Medizinische Universitätsklinik, Universität Mannheim, Mannheim, Germany

Florence Roufosse, Department of Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium

Peter F Weller, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Andrzej Hellmann, Department of Hematology, Medical University of Gdansk, Gdansk, Poland

Georgia Metzgeroth, Medizinische Universitätsklinik, Universität Mannheim, Mannheim, Germany

Kristin M Leiferman, Department of Dermatology, University of Utah, Salt Lake City, UT, USA

Michel Arock, LBPA, CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France

Karl Sotlar, Institute of Pathology, Ludwig Maximilians University, Munich, Germany

Joseph H Butterfield, Division of Allergic Diseases, Mayo Clinic Rochester, MN, USA

Sabine Cerny-Reiterer, Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria and Ludwig Boltzmann Cluster Oncology, Vienna, Austria

Matthias Mayerhofer, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

Peter Vandenberghe, © 2012 Peter Valent

*Author for correspondence: Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria and Ludwig Boltzmann Cluster Oncology, Währinger Gürtel 18-20, Vienna, Austria, Tel.: + 43 1 40400 5488, Fax: + 43 1 40400 4030, peter.valent@meduniwien.ac.at.

Financial & competing interests disclosure
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Center for Human Genetics, Katholieke Universiteit Leuven and University Hospital Leuven, Leuven, Belgium

Torsten Haferlach,
MLL Münchner Leukämielabor, Munich, Germany

Bruce S Bochner,
Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Jason Gotlib,
Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA, USA

Hans-Peter Horny,
Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany

Hans-Uwe Simon, and
Institute of Pharmacology, University of Bern, Switzerland

Amy D Klion
Eosinophil Pathology Unit, Laboratory of Parasitic Diseases, NIH/NIAID, Bethesda, MD, USA

Abstract

Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

Keywords
classification; eosinophilic leukemia; FIP1L1-PDGFRA; hypereosinophilia; hypereosinophilic syndromes; targeted therapy

Eosinophils are highly specialized granulocytic effector cells that produce and store diverse biologically active molecules, including cytotoxic, cytostimulatory proteins, lipid mediators, chemotactic peptides and cytokines [1-5]. Under various conditions, eosinophils can invade certain target organs after transendothelial migration and secrete their products into the surrounding tissue, thereby triggering local inflammation and tissue remodeling (Figure 1) [2-8]. When tissue and/or blood eosinophilia is marked and persistent, the term hypereosinophilia (HE) is appropriate. In patients with HE, eosinophil-derived substances may induce marked alterations in the microenvironment and thus chronic (and potentially irreversible) organ damage (Figure 1) [2-8]. In these patients, an array of signs and symptoms associated with eosinophilia may be present, and tissue inflammation is often accompanied by local (extracellular) deposition of eosinophil-derived proteins [2-8]. In a subset of these patients, tissue fibrosis and/or thrombosis may develop [2-8].
Blood and/or tissue HE is detectable in various inflammatory reactions, certain hematologic malignancies and sometimes in patients with solid tumors (Box 1) [9-17]. Reactive eosinophilia is typically found in patients with helminth infections, toxic or allergic drug reactions and atopic disorders (Box 1). Hematopoietic malignancies typically (but not always) accompanied by eosinophilia are myeloproliferative neoplasms (MPN), certain variants of acute myeloid leukemia (AML), a smaller subset of patients with myelodysplastic syndromes (MDS), some MDS/MPN overlap disorders, several (mostly T-cell-derived) lymphoproliferative disorders and (advanced) systemic mastocytosis (SM) (Box 1) [13,18-24]. These differential diagnoses should be considered in cases of unexplained HE, especially in the context of other blood count abnormalities. In such patients, a hematologic work-up, including bone marrow (BM) investigations with cytogenetics, FISH and molecular analyses, should be initiated [18-24]. In patients with myeloid or stem cell-derived neoplasms, eosinophils usually belong to the malignant clone. In these patients, fusion genes involving PDGFRA, PDGFRB, FGFR1 or other tyrosine kinases may be present (Table 1). This is of great importance given the fact that imatinib is highly effective in patients with PDGFRA or PDGFRB fusion genes, but not in neoplasms with FGFR1 fusion genes [18-28]. In chronic eosinophilic leukemia (CEL), the FIP1L1-PDGFRa fusion gene (and the related cytogenetic surrogate CHIC2 deletion by FISH) is detected in approximately 10–20% of all cases, and is thus the most frequent recurrent aberration in CEL (Table 1). Numerous other cytogenetic defects, such as loss of the Y chromosome, trisomy 8, trisomy 15, del(6q), del(20q) or i(17q), have also been reported [13]. Although most of these defects are rare in patients with eosinophil neoplasms, they support the clonal nature of HE.

During the past two decades, our knowledge about eosinophils, their biology, their specific functions and the mechanisms underlying HE and HE-related organ damage has improved substantially. Moreover, several proposals for the classification of HE-related disorders have been presented [17-24,29-33]. However, a number of open questions concerning the definition of HE and the classification of HE-related disorders remain. In this article, the authors review and discuss the recent literature and the current knowledge about eosinophils, eosinophil-induced organ damage and disorders presenting with HE. In addition, a diagnostic algorithm is proposed and related diagnostic parameters and treatment options are discussed.

**Origin, development, migration & activation of eosinophils: role of cytokines and peptide mediators**

Eosinophils are constantly replenished from a pool of pluripotent and lineage-committed hematopoietic progenitor cells in the BM (Figure 1) [34-36]. Bipotent precursor cells for eosinophils and basophils (CFU-eo/ba) are detectable in the BM and peripheral blood in healthy subjects as well as in patients suffering from allergic or other inflammatory reactions [34-38]. The production of eosinophils from multipotent and lineage-restricted progenitors is tightly controlled by a network of transcription factors (GATA-1, PU.1, c/EBPs and others) [39], growth factors and growth-inhibitory cytokines. Major growth factors for eosinophils are IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 (Table 2) [40-42]. These growth regulators are produced and secreted by (activated) immune cells such as T cells and mast cells, stromal cells and by eosinophils themselves [43-47]. Cell surface receptors for IL-3, IL-5 and GM-CSF are detectable on immature multipotent eosinophil progenitor cells, eosinophil-committed precursors and on mature eosinophils [48-50]. In line with this observation, these cytokines trigger not only proliferation of eosinophil progenitor cells, but also migration, adherence, cytokine production, activation and survival (by delayed apoptosis) of mature eosinophils (Figure 1 & Table 2) [48-51]. The
mobilization of eosinophils from the BM into the blood is regulated predominantly by IL-5 and eotaxin.

In addition to classical eosinophilic growth factors, other cytokines such as platelet-derived growth factor or NGF may play a role in the regulation of eosinophil development and function [52,53]. Although constitutively activated receptors for these cytokines may be involved in the development of HE, the effects of platelet-derived growth factor and NGF on eosinophil growth and function remain largely unknown (Table 2). Other cytokines and chemokine ligands (CCL), such as IL-16, vascular endothelial growth factor, CCL5 (RANTES), CCL11 (eotaxin), CCL24 (eotaxin-2), CCL26 (eotaxin-3) and platelet-activating factor, induce eosinophil migration and chemotaxis (Table 2) [54-68]. Most of these peptide mediators also trigger eosinophil activation, and some of them alter the adhesive properties of eosinophils (Table 2). Eosinophil-activating cytokines, such as IL-3 or IL-5, have also been described to enhance responsiveness of eosinophils to other peptides and cytokines [69]. Another related observation is that eosinophils isolated from inflamed tissue show enhanced migratory responses to various ligands compared with eosinophils in healthy tissue, and thus are in an activated (primed) state [70].

Finally, growth, survival and function of blood eosinophils are controlled by various ‘negative-regulators’ such as Siglec-8 and other cell surface inhibitory receptors [71,72]. It has also been described that TGF-β, IFN-α and IFN-γ suppress cytokine-induced growth and differentiation of human eosinophils in vitro (Table 2) [73–75]. In addition, TGF-β induces apoptosis in mature eosinophils [76]. Moreover, such soluble ‘negative-regulators’, like IFN-γ, reportedly counteract cytokine-induced migration of eosinophils [77]. All of these cytokine effects are considered to be mediated via specific receptors expressed on eosinophils. Eosinophils also possess receptors for glucocorticosteroids (GC), which inhibit eosinophil growth and function, and the number of GC receptors detectable in eosinophils correlates with the responses of these cells to GCs [78,79].

Expression of pathogenetically important cell surface receptors & other target antigens on eosinophils

Adhesion, migration, activation and survival of eosinophils are regulated by a network of cytokines, chemokines, other biologically active ligands and their receptors (Table 2). Indeed, eosinophils express a unique composition of cell surface receptors relevant to adhesion, homing and migration [58,59,61-65,80-82]. Several of these receptors are involved in the transmigration of eosinophils through endothelial monolayers [82-93], and thus in homing to tissues, which is critical for the development of a local eosinophil infiltrate typically seen in patients with HE-related organ damage (Figure 1). Eosinophils have also been reported to express L-selectin as well as E- and P-selectin ligands, various integrins, sialyl Lewis x, intercellular-adhesion molecule 1, the C3bi receptor (CD11b/CD18) and leukocyte-function antigen-1 (CD11a/CD18) [83-95]. In addition, eosinophils express leukosialin (CD43) and the leukocyte invasion receptor CD44. Whereas selectins are considered to mediate rolling and tethering of eosinophils on endothelial cell membranes and thus marginalization of eosinophils in the blood stream, integrins and other adhesion receptors mediate firm binding of eosinophils to endothelium before transmigration.

A number of proinflammatory cytokines and peptides promote the expression of adhesion molecules on eosinophils. Proinflammatory cytokines, such as IL-1, also promote the expression of ‘leukocyte-binding’ adhesion molecules on endothelial cells [85-97]. In line with this observation, eosinophils derived from inflamed tissues express higher levels of certain cell surface adhesion receptors. Conversely, GCs and other anti-inflammatory agents...
inhibit cytokine-induced expression of adhesion molecules on eosinophils and endothelial cells and thus eosinophil adhesion and transendothelial migration [96,97].

Eosinophils also express a number of other biologically active cell surface molecules, including complement receptors, Toll-like receptors, Fc receptors, gangliosides and various structural glycoproteins [79-83,98]. In addition, eosinophils express various lineage-restricted myeloid (target) antigens, such as Siglec-3 (CD33), and inhibitory receptors, including CD300a, EP4, SIRPa/CD172a and Siglec-8 [71,99,100]. CD300a and Siglec-8 are also expressed on basophils and mast cells, but are not expressed on other leukocytes [100,101]. Crosslinking of Siglec-8 on eosinophils is associated with apoptosis [102,103], whereas crosslinking of other inhibitory receptors described to date appears to downmodulate eosinophil responses to activation signals.

Altogether, a wide variety of surface molecules, including cytokine receptors, adhesion receptors, peptide (chemokine) receptors and siglec molecules, have been considered as potential targets of therapy in eosinophil-related disorders [101-106]. Whether such receptors can indeed be used as targets of drug therapy, and whether suitable targeted drugs can be developed, remains to be determined in preclinical studies and future clinical trials.

Eosinophil-derived mediators & their potential role in the pathogenesis of eosinophil-induced organ damage

Eosinophils are a rich source of proinflammatory mediators and cytokines, including hematopoietic growth factors, chemotactic and leukocyte-activating peptides, vasoactive mediators and profibrotic and/or angiogenic molecules [107-113]. Eosinophils also synthesize various lipid mediators, including cysteinyl leukotrienes and prostaglandins, which play a role in eosinophil biology, as eosinophils serve as de novo producers and target cells of these compounds [2,5,6]. In addition, eosinophils express several, more or less cell-specific basic proteins, including eosinophil cationic protein, eosinophil major basic proteins (MBP1 and MBP2), eosinophil peroxidase (EPO) and eosinophil-derived neurotoxin (EDN) [109,113-116]. The eosinophil granule proteins possess numerous biological properties, including direct toxicity to cells and microorganisms and the ability to activate cells and platelets.

With regard to HE-related organ damage, little is known about the pathogenetic role of eosinophil-derived mediators and cytokines in specific disease states. Based on known biological activities, several eosinophil-derived mediators and cytokines may contribute to local inflammation and recruitment of other leukocytes (Table 3). Other eosinophil-derived compounds may display cytotoxic properties in local tissue sites, assist in microbe killing (basic proteins, extracellular DNA traps and others) [117-119], counteract or degrade vasoactive molecules such as histamine (by eosinophil-derived histaminase), regulate lymphocyte function [110-113,120] or facilitate the development of fibrosis or thrombosis (Table 3) [107-113]. Of note, eosinophil products have been shown to promote fibrosis and thrombosis both by activating (and possibly damaging) endothelial cells and/or platelets and through antifibrinolytic or ‘prothrombotic’ actions mediated by expression and release of plasminogen activator inhibitor-2 [121] and other compounds. In fact, activated eosinophils and neoplastic eosinophils are a particularly rich source of proinflammatory, angiogenic and fibrogenic cytokines [45,107-114]. These eosinophil-derived mediators and cytokines may all act together to cause tissue damage in patients with HE.
Definition & classification of HE & HE-related organ damage (hypereosinophilic syndromes)

The normal eosinophil count in the peripheral blood ranges from 50 to 500 × 10^9/l. Blood eosinophilia can be divided into mild eosinophilia (up to 1500 × 10^9/l) and marked eosinophilia (>1500 × 10^9/l). The term HE should be used when marked blood eosinophilia has been documented and is persistent, with or without an additional marked tissue eosinophilia [33]. The defining features of ‘tissue HE’ have not been well characterized. Physiologically, substantial numbers of eosinophils are observed in the BM and in lymphatic organs as well as in the mucosal linings of the intestinal tract, especially the stomach, small intestine and colon [122]. In most other tissues and organs, however, even low numbers of eosinophils can be regarded as ‘eosinophilia’. True tissue HE is thus characterized by a local marked increase in eosinophils and/or marked deposition of eosinophil-derived proteins such as MBP [122-124]. Sometimes, the deposition of MBP is a predominant finding even in the absence of marked eosinophil accumulation [122-124]. Based on underlying conditions and etiology, several variant forms of HE exist for which the following terminology has recently been proposed [33]: a hereditary (familial) form (HE_F), HE of undetermined (clinical) significance (HE_US), primary (neoplastic) HE (HE_N) where eosinophils are considered to be clonal cells and secondary (reactive) HE (HE_R) where eosinophils are considered to be nonclonal cells expanded (and activated) by a reactive process [33]. Rarely, HE_R is triggered by a clonal process such as Hodgkin’s lymphoma or lung adenocarcinoma. In most cases, HE_R may be caused by eosinophilopoietic cytokines such as IL-5.

It is important to note that some patients with unexplained HE are asymptomatic at presentation and may not develop clinical manifestations for many years. These patients would initially be classified as HEUS. In patients with HEUS, no underlying (neoplastic or non-neoplastic) disease and no organ damage (or dysfunction) is detected. Some of these patients may develop signs and symptoms of eosinophil-induced organ damage in the followup. When organ damage accompanies HE (of any type), the term ‘hypereosinophilic syndrome’ (HES) is appropriate, provided that organ involvement is clinically relevant and can be attributed to HE [33]. This formulation closely matches to the traditional definition of HES [125–128] and remains a useful concept in clinical practice.

Similar to HE, HES should be divided into variants based on the underlying etiology [33]: idiopathic HES (with unknown etiology), primary (neoplastic) HES with an underlying clonal myeloid or stem cell disorder and secondary (reactive) HES where an underlying non-neoplastic or paraneoplastic condition is detected and is responsible for the expansion of nonclonal eosinophils. The lymphoid variant of HES (HE) was recognized as special situation. Although diagnostic criteria are not well established, this condition exhibits several features of reactive HES. Typically, lymphocytes from patients with lymphoid-variant HES show an aberrant phenotype, most often CD3^−/CD4^+, by flow cytometry. Monoclonyality of T cells as demonstrated by a positive (monoclonal) T-cell receptor rearrangement may also be detected. The clinical course tends to be indolent, with rare cases of evolution to T-cell lymphoma.

Although several different organ systems may be affected in HES, organ damage is typically restricted to certain organ systems, including the heart, lungs, skin, spleen, GI tract and central nervous system [125–129]. Endomyocardial fibrosis, development of intracavitary thrombi and occurrence of intravascular thrombosis represent serious cardiovascular complications of HE [123,129-135]. Endomyocardial fibrosis and thrombus formation are frequently seen in (untreated) patients with eosinophilic leukemias carrying the FIP1L1-PDGFRα fusion gene, but may also develop in other patients with HES. Patients with
FIP1L1-PDGFRA+ eosinophilic leukemia usually respond well to imatinib, and early treatment prevents irreversible organ damage in most patients [25-27,136-138]. Therefore, it is of great importance to start staging and genetic investigations early in order to document or exclude overt or imminent organ damage and to identify patients with a myeloid neoplasm likely to respond to imatinib therapy.

**Approach to the patient with HE & staging investigations**

A detailed medical history should be elicited from all patients with HE, including complete drug/medication and travel histories. Testing for potential helminth infections, including stool examination and serologies, should be guided by the exposure history. Nonessential drugs should be discontinued, and the chronology of events between exposure and the development of HE should be determined for the remaining medications. If no inciting drug or infection is identified, a thorough investigation for allergic/atopic or autoimmune disorders, blood cell disorders and other neoplastic conditions should be initiated [139,140]. This is usually performed in a stepwise approach. Important initial parameters that can be obtained from routine laboratory testing include a complete blood count with differential counts (confirmed by microscopy), routine chemistries (including tests of hepatic and renal function), levels of inflammatory markers and autoantibodies, serum IgE, vitamin B12 and tryptase levels, and a molecular test for FIP1L1-PDGFRA. BM investigation is warranted in all patients in whom HE remains unexplained or if a hematopoietic neoplasm is suspected. In patients with eosinophilic leukemia or other myeloid neoplasms, eosinophils are often (not always) immature and may display atypical morphology on Wright-Giemsa or May-Grunwald-Giemsa stained aspirate smears (Figure 2). Eosinophil granule abnormalities, including reduced granule size, leading to hypodense eosinophils, have also been described in patients with HE\(_N\) [141]. In some patients, the BM smear shows an increase in blast cells. However, HE\(_N\) can also occur with morphologically normal eosinophils, and in most patients, blast counts are normal at diagnosis.

BM investigations should also include a core biopsy with histology and immunohistochemistry (Figure 2). Ideally, an immunohistochemical marker panel including CD34, CD117, tryptase and CD25 should be applied [142]. In addition, cytogenetics, FISH and molecular analyses (seeking PDGFA+, PDGFRB and FGFR1 fusion genes, BCR-ABL, JAK2 V617F, KIT D816V as well as clonal TcR rearrangement) should be performed [23,33]. Many, but not all, of the molecular analyses are equally sensitive using peripheral blood cells. BM is usually required for cytogenetic examinations, although studies on peripheral blood can be successful if precursor cells circulate in the peripheral blood, which can be the case in HE\(_N\) and HES\(_N\). Finally, lymphocyte (T cell) phenotyping (by flow cytometry) should be performed in patients with HE to identify aberrant populations, most commonly CD3\(^+\)/CD4\(^+\) T cells, which have been associated with eosinophilopoietic cytokine production [143,144].

Concomitant with the evaluation described above, directed at identifying the etiology of the eosinophilia and depending in part on the signs and symptoms in the individual patient, the extent of eosinophil-mediated organ damage should be assessed. In all patients, these investigations should include a physical examination with thorough skin examination (by a dermatologist), detailed cardiologic evaluations including assays of serum troponins and an echocardiogram (and MRI if echocardiographic findings are difficult to interpret), assessment of pulmonary function, chest x-ray, abdominal imaging, and gastrointestinal examinations (with endoscopy if indicated).
Differential diagnoses, underlying disorders & diagnostic algorithm

As mentioned above, a number of different underlying conditions and disorders may induce HE with or without organ damage (HES). It is important to search for such disorders in patients with unexplained HE. When no underlying disease, family history, organ damage or other related disease (rare syndrome associated with eosinophilia) is discovered, the (provisional) diagnosis is HEUS (Figure 3) [33].

A number of reactive conditions and disorders can cause HE and may produce a clinical picture resembling HES (Box 1). Reactive hypereosinophilia (HE\textsubscript{R}) may develop in the setting of an underlying parasitic infection, drug allergy or neoplasm. Solid tumors, such as adenocarcinomas occurring in the lung, cervix or digestive tract, may produce paraneoplastic HE as a result of ectopic production of IL-5 or other cytokines by malignant cells. Similarly, there are hematological malignancies where eosinophilia is reactive, such as in Hodgkin’s lymphoma, T-cell lymphomas or B-cell acute lymphoblastic leukemia. On the other hand, HE may also develop as a clonal (neoplastic) process (HE\textsubscript{N}) in the setting of a hematopoietic malignancy (Figure 3).

Hematopoietic neoplasms that typically (but not always) present with HE include Ph\textsuperscript{+} chronic myeloid leukemia, certain variants of AML and some forms of advanced SM (Box 1) [12,13,23,24,33]. In addition, eosinophilia (but rarely HE) may occur in patients with MDS, Ph\textsuperscript{-} MPN and MDS/MPN overlap disorders. All of these malignancies should be classified according to WHO criteria [21,30-32]. The WHO classification of hematopoietic neoplasms has also defined specific categories (subvariants) for eosinophilic leukemias and other neoplasms in which abnormalities (mutant forms) of PDGFRA, PDGFRB or FGFR1 are detected [31,32]. However, although clearly relevant as driver mutants and potential therapeutic targets, it remains uncertain whether these fusion gene products can be recommended as major criteria of eosinophil-related neoplasms, or whether they should rather serve as minor or cocriteria in a revised classification of eosinophil neoplasms [23,33]. In fact, unlike chronic myeloid leukemia, where BCR/ABL\textsubscript{p210} is almost invariably associated with the disease, abnormalities in PDGFRA, PDGFRB or FGFR1 may alternatively be found in a wide variety of myelogenous malignancies, including MPN, MDS/MPN overlap neoplasms and acute leukemias, often without HE [31-33].

The WHO classification has also included the category ‘chronic eosinophilic leukemia – not otherwise specified’ (CEL NOS) [30,31]. Again, the current recommendation is to diagnose CEL NOS according to this classification and the proposed WHO criteria [31]. However, for the future, it may be advisable to revise this classification, and to adjust these criteria on the basis of novel markers and histomorphological criteria [33].

Finally, in other hematopoietic neoplasms, such as advanced mastocytosis, acute leukemias or stem cell-derived neoplasms, eosinophils may represent a mixture of clonal and nonclonal cells. The dilemma is that it is impossible to confirm (or exclude) clonality of eosinophils in these patients in daily practice.

Additional rare syndromes with specific organ pathologies can produce HE. These syndromes have been separated from the classical variants of HES because, although it is tempting to surmise that abundant eosinophils contribute to pathogenesis, the exact relationships between HE and the observed pathologies are often uncertain. It is important to be aware of these potential diagnoses when approaching a patient with HE. These disorders include, among others, episodic angioedema and eosinophilia (Gleich’s syndrome), Churg–Strauss syndrome (CSS), Eosinophilia Myalgia syndrome, Omenn syndrome and the Hyper-IgE syndrome (Table 4). Gleich’s syndrome is characterized by cyclic, recurrent angioedema, associated with peripheral blood HE and elevated polyclonal IgM [145,146].

In
some cases, lymphocyte phenotyping reveals abnormal (activated) T-cell subsets (CD4+ T cells with decreased or absent expression of surface CD3). Therefore, Gleich’s syndrome is also regarded as a special manifestation of the lymphoid variant of HES [140,144,147]. CSS is characterized by necrotizing vasculitis often accompanied by asthma and eosinophilia [148-150]. Antineutrophil cytoplasmic antibodies are detectable in a subset (less than 50%) of CSS patients [148-151]. Eosinophilia Myalgia syndrome is defined by severe myalgia and is often accompanied by neurologic symptoms and skin changes. Epidemic cases were associated with l-tryptophan exposure and with the toxic oil syndrome (Table 4) [151-153]. Omenn syndrome and the Hyper-IgE syndrome are rare inherited immunodeficiency syndromes accompanied by eosinophilia (Table 4). There are other clinical conditions and syndromes characterized by the presence of eosinophilia, sometimes resembling HES. In many (if not most) of these conditions, eosinophilia is likely triggered by aberrant lymphocyte production of eosinophilopoietic cytokines such as IL-5 [143,144].

Management & therapy of patients with HE & HE-related disorders

In patients with HEUS and HEF, it seems appropriate to follow-up the patient without treatment provided that there are no signs or symptoms of eosinophil-related organ damage despite careful medical monitoring. Notably, both HEUS and HEF must be regarded as provisional diagnoses, since in both conditions, organ damage may develop over time, or a hematologic or other underlying disease may eventually be detected.

The reactive form of HE is best managed by treating the underlying disease. In many cases, symptomatic therapy is sufficient to control problems related to eosinophil activation in these patients. However, it is not appropriate to treat HE per se in these patients, such as when no eosinophil-related organ damage (HES) is present. If the underlying disease is accompanied by HES and cannot be managed with or is resistant to conventional (symptomatic) therapy, the eosinophil count can usually be suppressed with glucocorticosteroids [140,154–157]. These drugs act directly and indirectly to reduce eosinophilia by inducing apoptosis in eosinophils and eosinophil precursors, and by inhibiting production of eosinophilopoietic cytokines by T lymphocytes (Table 5).

For patients presenting with HES in the absence of a detectable underlying cause (so-called idiopathic HES) or with lymphoid variant HES, glucocorticoids are also indicated, but side effects and poor tolerance are often dose-limiting. The most commonly used corticosteroid-sparing agents in this setting are hydroxyurea and IFN-α (Table 5) [140,154–157]. Mepolizumab, an anti-IL-5 antibody, has also been shown to be a safe and effective steroid-sparing agent for patients with FIP1L1/PDGFRA-negative HES (idiopathic and lymphoid variants) but is not commercially available [158–161].

In contrast to patients with idiopathic HES and reactive HES, those with HES in the setting of a clonal (neoplastic) BM disease (HESN) do not typically respond to glucocorticoid therapy. Although IFN-α and hydroxyurea have been used with some success, the mortality in this subgroup of patients with HES remained high until the recent development of therapeutic agents targeting specific molecular defects in CEL and other hematopoietic neoplasms with eosinophilia. Notably, a number of molecular targets related to CEL or other hematopoietic malignancies presenting with eosinophilia have been identified in the past decade [13,18–24,162–165]. It is essential to define any molecular defects (and thereby therapeutic targets), the exact histomorphological diagnosis and extent of organ involvement (organ damage) by appropriate staging investigations in order to develop an optimal treatment plan.
The most frequent fusion oncoprotein and target detectable in patients with CEL is FIP1L1/PDGFRα [18–24]. This fusion gene product is a target of imatinib and also sensitive to other tyrosine kinase inhibitors (TKIs) such as nilotinib or dasatinib [18–24, 166–168]. A number of other fusion gene-related oncoproteins that serve as targets of imatinib have also been described (less commonly) in eosinophil disorders [18–24]. Most of these fusion genes involve PDGFRα or PDGFRβ, and are sensitive to imatinib, whereas FGFR1 mutants are resistant [25–28].

Based on clinical trials, imatinib is considered standard first-line therapy in patients with FIP1L1/PDGFRα+ eosinophilia (Table 5) [25–27,137,169,170]. Although most patients show a long-lasting response to a standard start dose of 100 mg daily or less, some patients require a dose of 400 mg daily [25–27,137,169,170]. Very few patients may develop resistance, which is mainly caused by rare FIP1L1/PDGFRα point mutations associated with decreased (or loss of) drug-binding capacity [26,170–172]. For these patients, novel TKIs such as sorafenib, nilotinib or midostaurin may be considered (in clinical trials) [173–176]. Another approach is to apply alternative cytoreductive agents, such as IFN-α, hydroxyurea or experimental drugs, including new antileukemic, targeted small-molecule-type drugs or targeted antibodies [177,178]. In patients who progress to acute leukemia, high-dose chemotherapy and hematopoietic stem cell transplantation must be considered.

Rarely, the FIP1L1/PDGFRα fusion gene is detected in untreated patients with a longstanding apparently stable course of HE without evidence of organ damage. Although a polymorphism in the IL-5RA gene has been associated with disease severity [179], there are as yet no predictive markers that can define the exact risk of progression or development of organ damage in these patients. Moreover, imatinib is a very well-tolerated drug without documented long-term side effects or additional mutagenic effects of the drug in leukemic patients (except in pregnant patients). Therefore, the current recommendation is to treat even asymptomatic patients with CEL early with imatinib to prevent the development of irreversible complications, should disease progression occur.

In patients with FGFR1 mutants, imatinib is not effective and thus is not recommended. In many of these patients, the condition behaves as an aggressive stem cell disease or a leukemia/lymphoma syndrome (also known as 8p11 syndrome). For these patients, chemotherapy plus allogeneic stem cell transplantation or novel alternative targeted drugs [180-182] are potential treatment options. In other patients with myeloid neoplasms associated with HE, the treatment plan should be based on the underlying disease and the availability of relevant therapeutic agents.

Concluding remarks & expert commentary

HE is an important diagnostic checkpoint in various hematologic and nonhematologic disorders. In patients with HE, it is important to document or exclude an underlying neoplastic or non-neoplastic disease and to document or exclude the presence of definitive or imminent HE-related organ damage (HES). Several immunological, serological and molecular/cytogenetic markers are available to delineate variants of HE, HES and underlying conditions. Independent of the underlying disease, patients with overt or imminent organ damage (HES) are candidates for early therapeutic intervention. In those with secondary HES, treatment of the underlying disease is usually effective. In some patients with HES, IL-5-targeting antibodies may work. In patients who have mutated variants of PDGFRα or PDGFRβ, imatinib or other PDGFR-targeting tyrosine kinase inhibitors are usually effective. Our increasing knowledge about eosinophilia, the development of more specific predictive biomarkers, markers of eosinophil clonality and
gene chip profiling-based evaluations, as well as the development of new therapeutic approaches should improve diagnosis and prognosis of eosinophil disorders in the future.

**Five-year view**

During the next 5 years, in addition to recently identified markers, novel markers that distinguish varied eosinophil diseases and their therapeutic targets will be identified. Using such new parameters and molecular targets, the proposed definitions, criteria and classification of eosinophil diseases may be updated and refined. With regard to the diversity of eosinophilic diseases, we contribute our collective classification proposals and their bases. We would welcome the WHO in creating a new multidisciplinary consensus classification of eosinophilic diseases that includes clinical, histomorphological, cytogenetic and molecular parameters.

**Acknowledgments**

P Valent has received a Research Grant from Novartis and a Research Grant from BMS, as well as honoraria from Novartis and BMS. AD Klein is supported by the Intramural Program of the NIAID, NIH. KM Leiferman, HU Simon and GJ Gleich have been supported by grants from GSK. M Arock received honorarium from Novartis. P Vandenberghhe is a Senior Clinical Investigator of FWO-Vlaanderen. T Haferlach is part owner of the Munich Leukemia Laboratory. A Reiter received Honoraria from Novartis and BMS. BS Bochner is a co-author on existing and pending Siglec-8-related patents. If Siglec-8-related products are developed in the future, BS Bochner may be entitled to a share of royalties received by Johns Hopkins University on the potential sales of such products. The terms of this arrangement are being managed by Johns Hopkins University in accordance with its conflict of interest policies. This study was supported by a research grant of the Medical University of Vienna and by the Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA.

No writing assistance was utilized in the production of this manuscript.

**References**

Papers of special note have been highlighted as:

- of interest


First proposal for a classification of eosinophil disorders that is based not only on morphologic criteria but also on cytogenetic and molecular parameters.


48•. Lopez AF, Vadas MA, Woodcock JM, et al. Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on


**Box 1. Major causes of hypereosinophilia**

- **Non-neoplastic reactive conditions (secondary/reactive HE)**
  - Helminth infections
  - Scabies, other infestations
  - Allergic bronchopulmonary aspergillosis
  - Drug reactions (allergic or toxic)
  - Other allergic reactions
  - Atopic diseases
  - Chronic graft-versus-host disease
  - Chronic inflammatory disorders (e.g., IBD)
  - Autoimmune diseases
  - L-HES

- **Neoplastic conditions with secondary/reactive HE (paraneoplastic)**
  - Hodgkin’s disease
  - B- or T-cell lymphoma/leukemia
  - Langerhans cell histiocytosis
  - Solid tumors/malignancy

- **Myeloid neoplasms and stem cell neoplasms (primary HE)**
  - Chronic eosinophilic leukemia – NOS
  - Hematopoietic neoplasms with eosinophilia and abnormalities in *PDGFRα*
  - Hematopoietic neoplasms with eosinophilia and abnormalities in *PDGFRB*
  - Hematopoietic neoplasms with eosinophilia and abnormalities in *FGFR1*
  - CML with eosinophilia
  - AML with inv(16) and eosinophilia (AML-M4-eo)
  - JAK2 V617F+ MPN with eosinophilia
  - ASM with eosinophilia
  - MDS with eosinophilia
  - MPN/MDS overlap syndromes with eosinophilia

- **Idiopathic: HEUS**

†In most cases, eosinophilia may be triggered by eosinopoietic cytokines.
‡In most patients, eosinophils are clonal cells (neoplastic eosinophils).
§Eosinophilia often develops in patients with ASM, but may also occur in patients with indolent systemic mastocytosis.
AML: Acute myeloid leukemia; ASM: Aggressive systemic mastocytosis; CML: Chronic myeloid leukemia; HE: Hypereosinophilia; HEUS: Hypereosinophilia of undetermined (unknown) significance; IBD: Inflammatory bowel disease; L-HES: Lymphoid variant of hypereosinophilic syndrome; MDS: Myelodysplastic syndrome; MPN: Myeloproliferative neoplasm; NOS: Not otherwise specified.
Key issues

- Eosinophils represent a distinct hematopoietic cell lineage with unique features. Chronic (hyper)eosinophilia may be accompanied by a characteristic pattern of organ damage.
- Hypereosinophilia (HE) is an important checkpoint in the diagnostic algorithm.
- Independent of the underlying disease, HE-associated organ damage is called hypereosinophilic syndrome (HES).
- Depending on the underlying disease, HE and HES can be further subclassified.
- In hematologic neoplasms with HE, eosinophils are usually clonal cells, although direct proof of eosinophil clonality is rarely obtained.
- Close clinical follow-up of HE of undetermined significance (HEUS) is necessary to monitor for development of HES and/or an underlying disease.
- Treatment of HES depends on the underlying disease and on the presence of identified therapeutic targets.
- Complete staging of all organ systems, including the skin, lung, heart, bone marrow and blood and GI tract, is essential in the evaluation of all patients with unexplained HE.
- Patients with myeloid or stem cell neoplasms and eosinophilia caused by abnormalities in PDGFRA or PDGFRB should be treated with imatinib.
Eosinophils originate from multipotent and lineage-restricted hematopoietic progenitor cells. Eosinophil progenitors reside in the bone marrow but are also detectable in the peripheral blood. Eosinophil development is regulated by eosinophilopoietic cytokines (IL-3, GM-CSF and IL-5) and takes place primarily in the bone marrow. Cytokine-induced HE in the peripheral blood is often accompanied by tissue HE. Activation of eosinophils and activation of endothelial cells contribute to endothelial transmigration and infiltration of inflamed tissues. Eosinophil adhesion to endothelium and transmigration are mediated by certain homing receptors. Migration and accumulation of eosinophils in (inflamed) tissues are mediated by chemotactic peptides (chemokines), cytokines and other mediators. Eosinophil accumulation is also triggered by delayed eosinophil apoptosis, another cytokine-mediated phenomenon, in local tissue sites. Activation of eosinophils leads to degranulation and mediator secretion in tissues, with consequent organ damage, which may be accompanied by fibrosis and/or thrombosis and by deposition of eosinophil granule proteins. HE: Hypereosinophilia; GM-CSF: Granulocyte/macrophage colony-stimulating factor; IL: Interleukin; PAF: Platelet-activating factor; SCF: Stem cell factor.
Figure 2. Hypereosinophilia assessed by microscopy
(A) Giemsa-stained bone marrow section in a patient with eosinophilic leukemia. Note the massive eosinophil infiltrate replacing the normal bone marrow. (B) Circulating immature eosinophils in a patient with FIP1L1/PDGFRα+ chronic eosinophilic leukemia. (C) & (D) Bone marrow biopsy sections obtained from a patient with FIP1L1/PDGFRα+ chronic eosinophilic leukemia. Sections were incubated with an antibody directed against eosinophil major basic protein and analyzed by indirect immunohistochemistry.
Figure 3. Diagnostic algorithm for patients with hypereosinophilia

After having established that HE is present, the cause and clinical significance of HE need to be explored. With regard to the cause, the patient is examined for signs of a reactive process (helminth infection, drug allergy or others), evidence of a myeloid or stem cell neoplasm (where eosinophils usually are neoplastic cells), or of other malignancies. In rare cases, familial HE is diagnosed. When no underlying condition and no signs of overt organ damage are found, the (provisional) diagnosis HE\textsuperscript{US} is established, and the patient is carefully monitored. In the case of secondary (reactive or paraneoplastic) HE or clonal (neoplastic) HE, the final diagnosis is determined using the WHO criteria and other established criteria. When HE is accompanied by specific (eosinophil-induced) organ damage, diagnosis of HES is established. HES can occur in any type of HE and can present as secondary (reactive) HES, primary (neoplastic) HES, or idiopathic HES. Rare syndromes presenting with eosinophilia, such as the CCS, Gleich’s syndrome and other syndromes, must also be considered based on clinical findings.

CCS: Churg-Strauss syndrome; HE: Hypereosinophilia; HE\textsubscript{N}: Clonal/neoplastic HE; HE\textsubscript{R}: Reactive HE; HE\textsubscript{US}: HE of undetermined significance; HES: Hypereosinophilic syndrome; HES\textsubscript{N}: Primary/neoplastic HES; HES\textsubscript{R}: Reactive HES; NHL: Non-Hodgkin’s lymphoma.
Table 1
Gene abnormalities and cytogenetic defects in myeloid and stem cell neoplasms associated with eosinophilia

<table>
<thead>
<tr>
<th>Molecular defect fusion gene/mutation</th>
<th>Cytogenetic anomaly</th>
<th>Estimated frequency in MPN-eo (%)</th>
<th>Estimated frequency in CEL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDGFRA gene abnormalities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIP1L1-PDGFR A</td>
<td>del(4q12)</td>
<td>5</td>
<td>10–20</td>
</tr>
<tr>
<td>STRN-PDGFR A</td>
<td>t(2;4)(q22;q12)</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>CDK5RAP2-PDGFR A</td>
<td>ins(9;4)(q33;12q12q25)</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>KIF5B-PDGFR A</td>
<td>t(4;10)(q12;p11)</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>BCR-PDGFR A</td>
<td>t(4;22)(q12;q11)</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>ETV6-PDGFR A</td>
<td>t(4;12)(q12;p13)</td>
<td>&lt;5</td>
<td>5</td>
</tr>
<tr>
<td>PDGFRB gene abnormalities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPM3-PDGFR B</td>
<td>t(1;5)(q21;q33)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>PDIE4DP-PDGFR B</td>
<td>t(1;5)(q23;q33)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>SPTBN1-PDGFR B</td>
<td>t(2;5)(p16q33)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>WDR48-PDGFR B</td>
<td>t(3;5)(p22;q33)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>GOLGA4-PDGFR B</td>
<td>t(3;5)(p22;q33)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>PRKG2-PDGFR B</td>
<td>t(4;5;5)(q21;33)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>HIP1-PDGFR B</td>
<td>t(5;7)(q33;q11)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>KANK1-PDGFR B</td>
<td>t(5;9)(q33;p24)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>CCRD6-PDGFR B</td>
<td>t(5;10)(q33;q21)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>CAPRIN1-PDGFR B</td>
<td>t(1;5;11)(p34;q33;p13)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>ERC1-PDGFR B</td>
<td>t(5;12)(q33;p13)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>BIN2-PDGFR B</td>
<td>t(5;12)(q33;q13)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>ETV6-PDGFR B</td>
<td>t(5;12)(q33;p13)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>SART3-PDGFR B</td>
<td>t(5;12)(q33;q24)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>GIT2-PDGFR B</td>
<td>t(5;12)(q33;q24)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>CCRD8C-PDGFR B</td>
<td>t(5;14)(q33;q32)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>TRIP11-PDGFR B</td>
<td>t(5;14)(q33;q32)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>NIN-PDGFR B</td>
<td>t(5;14)(q33;q24)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>TP53BP1-PDGFR B</td>
<td>t(5;15)(q33;q22)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>NDE1-PDGFR B</td>
<td>t(5;16)(q33;p13)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>SPEC2-PDGFR B</td>
<td>t(5;17)(q33;p11)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>MYO18A-PDGFR B</td>
<td>t(5;17)(q33;q11)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>RABEP1-PDGFR B</td>
<td>t(5;17)(q33;p13)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>FGFR1 gene abnormalities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FGFR1OP-FGFR1</td>
<td>t(6;8)(q27;p11)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>TRIM24-FGFR1</td>
<td>t(7;8)(q34;p11)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>CEP110-FGFR1</td>
<td>t(8;9)(p12;q33)</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
</tbody>
</table>
Molecular defects refer to data reported in the available literature. Histomorphologic phenotypes and variants reported in these patients include CEL, myeloproliferative syndromes with eosinophilia (MPN-eo), myelodysplastic syndromes with eosinophilia (MDS-eo), MPN/MDS overlap syndromes with eosinophilia (MPN/MDS-eo), chronic myelomonocytic leukemia with eosinophilia, chronic myeloid leukemia, atypical chronic myeloid leukemia with eosinophilia, systemic mastocytosis with eosinophilia, aggressive systemic mastocytosis with eosinophilia, acute myeloid leukemia with eosinophilia, acute eosinophilic leukemia and stem cell syndromes, including the stem cell leukemia lymphoma syndrome and the 8p11 syndrome. By far the most frequent fusion gene is FIP1L1-PDGFRα, which is found in 5–15% of all cases with nonreactive HE. Other more rarely but recurrently identified molecular abnormalities (>5 cases reported) include ZMYM2-FGFR1 (formerly known as ZNF198-FGFR1), FGFR1OP-FGFR1 (FOP-FGFR1), CEP110-FGFR1, PCM1-JAK2, ETV6-JAK2, KIT D816V, CCDC6-PDGFRB (H4/D10S170) and ETV6-PDGFRB (TEL-PDGFRB). The majority of PDGFRB fusion genes have only been reported in single individuals.

CELM: Chronic eosinophilic leukemia; MPN-eo: Myeloproliferative neoplasms with eosinophilia.
Table 2
Cytokines, peptides and receptors regulating growth and function of eosinophils

<table>
<thead>
<tr>
<th>Cytokine/peptide</th>
<th>Effects on eosinophils</th>
<th>Known receptor/s (R)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-2</td>
<td>Activation of CD25+ eosinophils †</td>
<td>IL-2RA/CD25</td>
</tr>
<tr>
<td>IL-3</td>
<td>Differentiation, survival, adhesion, migration, activation, priming</td>
<td>IL-3R/CD123+βC</td>
</tr>
<tr>
<td>IL-4</td>
<td>Priming for effects of chemotaxins</td>
<td>IL-4R/CD124</td>
</tr>
<tr>
<td>IL-5</td>
<td>Differentiation, survival, adhesion, migration, activation, priming</td>
<td>IL-5R/CD125+βC</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>Differentiation, survival, adhesion, migration, activation, priming</td>
<td>GM-CSFR/CD116+βC</td>
</tr>
<tr>
<td>IL-10</td>
<td>Inhibitory (activation, survival)</td>
<td>IL-10R</td>
</tr>
<tr>
<td>IL-12</td>
<td>Inhibitory (activation)</td>
<td>IL-12R</td>
</tr>
<tr>
<td>IL-13</td>
<td>Unknown</td>
<td>IL-13R</td>
</tr>
<tr>
<td>IL-16</td>
<td>Activation, priming</td>
<td>CD4, CD9(?), CCR3</td>
</tr>
<tr>
<td>IL-25</td>
<td>Survival, activation</td>
<td>IL-25R</td>
</tr>
<tr>
<td>IL-27</td>
<td>Survival, activation</td>
<td>IL-27R</td>
</tr>
<tr>
<td>IL-33</td>
<td>Adhesion, migration, activation</td>
<td>IL-33R/ST2</td>
</tr>
<tr>
<td>VEGF</td>
<td>Chemotaxis, activation</td>
<td>VEGFR-1/FLT-1</td>
</tr>
<tr>
<td>Angiopoietin-1</td>
<td>Chemotaxis, activation?</td>
<td>Tie-2/TEK</td>
</tr>
<tr>
<td>PDGF</td>
<td>Activation?</td>
<td>PDGFRα/β</td>
</tr>
<tr>
<td>FGF</td>
<td>Activation?</td>
<td>FGFR1</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>Inhibitory (differentiation, activation)</td>
<td>TGF-β1R</td>
</tr>
<tr>
<td>TGF-β2</td>
<td>Inhibitory (differentiation, activation?)</td>
<td>TGF-β2R</td>
</tr>
<tr>
<td>IFN-α</td>
<td>Inhibitory (growth)</td>
<td>IFN-α-R</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>Inhibitory (growth, migration)</td>
<td>IFN-γ-R</td>
</tr>
<tr>
<td>RANTES (CCL5)</td>
<td>Chemotaxis, activation</td>
<td>CCR3</td>
</tr>
<tr>
<td>MCP-3 (CCL7)</td>
<td>Chemotaxis, activation</td>
<td>CCR3</td>
</tr>
<tr>
<td>MCP-4 (CCL13)</td>
<td>Chemotaxis, activation</td>
<td>CCR3</td>
</tr>
<tr>
<td>Eotaxin (CCL11)</td>
<td>Chemotaxis, activation</td>
<td>CCR3</td>
</tr>
<tr>
<td>Eotaxin-2 (CCL24)</td>
<td>Chemotaxis, activation</td>
<td>CCR3</td>
</tr>
<tr>
<td>Eotaxin-3 (CCL26)</td>
<td>Chemotaxis, activation</td>
<td>CCR3</td>
</tr>
<tr>
<td>SDF-1 (CXCL12)</td>
<td>Chemotaxis</td>
<td>CXCR4</td>
</tr>
<tr>
<td>PAF</td>
<td>Chemotaxis, activation</td>
<td>PAF-R</td>
</tr>
<tr>
<td>Complement factors C3a and C5a</td>
<td>Chemotaxis, activation</td>
<td>C3aR, C5aR</td>
</tr>
<tr>
<td>Toll-like R receptor</td>
<td>Survival, activation</td>
<td>TLR1, 4, 7, 9, 10</td>
</tr>
<tr>
<td>VIP</td>
<td>Chemotaxis</td>
<td>VIP-Rs</td>
</tr>
<tr>
<td>GCs</td>
<td>Inhibitory (activation)</td>
<td>GC-R</td>
</tr>
</tbody>
</table>

IL: Interleukin; CCL: Chemokine ligand; GC: Glucocorticosteroid; GM-CSF: Granulocyte/macrophage colony-stimulating factor; MCP: Monocyte chemotactic protein; PAF: Platelet-activating factor; R: Receptor; VIP: Vasointestinal peptide.

† Eosinophils derived from patients with hypereosinophilic syndromes (activated eosinophils) frequently express CD25.
Table 3
Major eosinophil products and their potential role in the development of hypereosinophilia

<table>
<thead>
<tr>
<th>Eosinophil product</th>
<th>Effects potentially relevant to HE-related organ damage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic proteins</strong></td>
<td></td>
</tr>
<tr>
<td>MBP</td>
<td>Direct toxic effect, cytostimulatory</td>
</tr>
<tr>
<td>ECP</td>
<td>Direct toxic effect, mucus secretion, fibrosis</td>
</tr>
<tr>
<td>EDN</td>
<td>Direct toxic effect, TLR2 ligand effects, RNase</td>
</tr>
<tr>
<td>EPO</td>
<td>Direct toxic effect, cytostimulatory</td>
</tr>
<tr>
<td><strong>Enzymes</strong></td>
<td></td>
</tr>
<tr>
<td>Lysophospholipase</td>
<td>Direct toxic effect</td>
</tr>
<tr>
<td>Phospholipase D</td>
<td>LFA-dependent adhesion</td>
</tr>
<tr>
<td>Arylsulphatase B</td>
<td>Lysosomal hydrolase</td>
</tr>
<tr>
<td>Histaminase</td>
<td>Histamine degradation</td>
</tr>
<tr>
<td>Catalase</td>
<td>Direct toxic effect</td>
</tr>
<tr>
<td>Acid phosphatase</td>
<td>Direct toxic effect</td>
</tr>
<tr>
<td>Nonspecific esterases</td>
<td>Direct toxic effect</td>
</tr>
<tr>
<td>Hexosaminidase</td>
<td>Direct toxic effect</td>
</tr>
<tr>
<td><strong>Cytokines</strong></td>
<td></td>
</tr>
<tr>
<td>IL-1α</td>
<td>Endothelial activation, inflammation</td>
</tr>
<tr>
<td>IL-2</td>
<td>Activation of T lymphocytes</td>
</tr>
<tr>
<td>IL-3</td>
<td>Amplification of eosinophilia</td>
</tr>
<tr>
<td>IL-4</td>
<td>B-cell maturation and mast cell activation</td>
</tr>
<tr>
<td>IL-5</td>
<td>Amplification of eosinophilia</td>
</tr>
<tr>
<td>IL-6</td>
<td>Lymphocyte maturation</td>
</tr>
<tr>
<td>IL-8</td>
<td>Leukocyte recruitment and activation</td>
</tr>
<tr>
<td>IL-13</td>
<td>Bronchial hyper-reactivity, mucus production, B-cell maturation</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>Leukocyte/eosinophil activation</td>
</tr>
<tr>
<td>TGF-α</td>
<td>Fibrosis, growth inhibition</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Fibrosis, growth inhibition</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Endothelial activation, inflammation, cachexia</td>
</tr>
<tr>
<td>OSM</td>
<td>Fibrosis, angiogenesis</td>
</tr>
<tr>
<td><strong>Chemokines</strong></td>
<td></td>
</tr>
<tr>
<td>MIP-1α (CCL3)</td>
<td>Leukocyte recruitment and activation</td>
</tr>
<tr>
<td>RANTES (CCL5)</td>
<td>Leukocyte recruitment and activation</td>
</tr>
<tr>
<td>Eotaxin (CCL11)</td>
<td>Further eosinophil recruitment</td>
</tr>
<tr>
<td><strong>Membrane-derived mediators</strong></td>
<td></td>
</tr>
<tr>
<td>LTC4</td>
<td>Mucus secretion</td>
</tr>
<tr>
<td>PAF</td>
<td>Bronchoconstriction, edema formation</td>
</tr>
<tr>
<td>15-HETE</td>
<td>Diverse effects on blood and tissue cells</td>
</tr>
<tr>
<td>Eosinophil product</td>
<td>Effects potentially relevant to HE-related organ damage</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>PGE1 and PGE2</td>
<td>Diverse effects on platelets, endothelial cells, fibroblasts and other tissue cells</td>
</tr>
<tr>
<td>TXB2</td>
<td>Platelet aggregation</td>
</tr>
</tbody>
</table>

**Antifibrinolytic mediators**

| PAI-2             | Antifibrinolytic and prothrombotic                      |

**Extracellular DNA traps**

| Direct toxic effect (on bacteria) |

### Table 4
Examples of rare syndromes accompanied by eosinophilia

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gleich’s syndrome</td>
<td>Cyclic recurrent angioedema and elevated IgM, sometimes with clonal T cells</td>
</tr>
<tr>
<td>Churg–Strauss syndrome</td>
<td>Necrotizing vasculitis with eosinophilia (ANCA(^+) and ANCA(^-) subvariants)</td>
</tr>
<tr>
<td>Eosinophilia myalgia syndrome</td>
<td>Severe myalgia, often accompanied by neurologic symptoms and skin changes; epidemic cases have been attributed to l-tryptophan exposure (subvariant: toxic oil syndrome)</td>
</tr>
<tr>
<td>Omenn syndrome</td>
<td>Severe combined immunodeficiency plus HE, often with erythroderma, hepatosplenomegaly or lymphadenopathy, autosomal recessive genetic disease (recurrent mutations in (RAG1) or (RAG2))</td>
</tr>
<tr>
<td>Hyper-IgE syndrome</td>
<td>Hereditary immunodeficiency syndrome with HE and elevated levels of IgE, often with eczema and facial anomalies. Known gene mutations – autosomal dominant variant: (STAT3) mutations; autosomal recessive variant: (DOCK8) mutations</td>
</tr>
</tbody>
</table>

ANCA: Antineutrophil cytoplasmic antibodies; HE: Hypereosinophilia.
### Table 5

**Selected treatment options in patients with eosinophil disorders**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Major indication(s)</th>
<th>Mode of drug action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucocorticosteroids</strong></td>
<td>Reactive eosinophilia/HES</td>
<td>Inhibition of production of eosinophilopoietic cytokines by T cells and direct apoptosis-inducing effect on eosinophils and eosinophil precursor cells</td>
</tr>
<tr>
<td></td>
<td>Lymphoid variant of HES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eosinophilia syndromes</td>
<td></td>
</tr>
<tr>
<td><strong>Mepolizumab† and other</strong></td>
<td><strong>FIP1L1/PDGFR</strong>-negative HES (idiopathic and lymphoid variants)</td>
<td>Blocking of IL-5 activity</td>
</tr>
<tr>
<td><strong>anti-IL-5 antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Imatinib</strong></td>
<td>Myeloid, stem cell and eosinophil disorders with rearranged <strong>PDGFR</strong> genes</td>
<td>Inhibition of PDGFR kinase activity</td>
</tr>
<tr>
<td><strong>IFN-α</strong></td>
<td><strong>FIP1L1/PDGFR</strong>-negative HES</td>
<td>Inhibition of proliferation of eosinophil progenitors; reduces production of GM-CSF and IL-5</td>
</tr>
<tr>
<td><strong>Hydroxyurea</strong></td>
<td>Palliative drug for advanced myeloid, stem cell or eosinophil neoplasms, steroid-refractory HES</td>
<td>Controls progenitor cell proliferation (apoptosis induction)</td>
</tr>
<tr>
<td><strong>Polychemotherapy and stem</strong></td>
<td>Advanced myeloid stem cell or eosinophil neoplasm (acute leukemias)</td>
<td>Eradication of neoplastic stem cells (immunotherapy)</td>
</tr>
<tr>
<td><strong>cell transplantation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Experimental agents including novel TKIs‡ and various targeting antibodies§</strong></td>
<td>Refractory HES and CEL</td>
<td>–</td>
</tr>
</tbody>
</table>

**CEL:** Chronic eosinophilic leukemia; **GM-CSF:** Granulocyte/macrophage colony-stimulating factor; **HES:** Hypereosinophilic syndrome; **PDGFR:** PDGF receptor; **TKI:** Tyrosine kinase inhibitor.

† Mepolizumab is currently only available for compassionate use for life-threatening HES refractory to standard therapies. Other agents targeting the IL-5 axis, including reslizumab and MEDI-563, are not currently available outside of clinical trials.

‡ In rare cases of CEL, imatinib resistance develops because of secondary mutations in FIP1L1-PDGFR; in these cases, some of the novel TKIs may overcome drug resistance.

§ Alemtuzumab, an antibody against CD52 (CAMPATH) has been shown to be effective in some patients with the lymphoid variant of HES.